Clinical Trials Browser

Completed × ibrutinib × 30 days × Clear all

NCT02997761 2026-04-07

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

Phase 2 Completed

Burkitt Lymphoma

NCT02518555 2026-04-06

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell